title: [A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans].
abstract: A case of far advanced gastric cancer with multiple liver metastasis (H3) was treated with transarterial intermittent chemotherapy (5-FU: 250 mg/week, Farmorubicin: 10 mg/4 weeks, MMC: 4 mg/2 weeks) and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans. The CT examination and endoscopy showed regression of the tumor and the patient was discharged from the hospital. LPSp was given at the concentration of 0.1 microgram initially, and the dose was gradually increased. Finally, the dose of LPSp was increased up to 70 micrograms. No serious side effect except fever was observed. The serum TNF-alpha levels were elevated and, histologically, CD 8(+) lymphocyte dominantly infiltrated around the tumor. These findings clearly indicated the immunological anticancer effect of LPSp. Intradermal administration of LPSp is a promising new adjuvant therapy to improve QOL without serious side effect.
authors.affiliation: Dept. of Surgery, Teikyo University Mizonokuchi Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Kasugai
authors.forename: J
authors.initials: J
authors.lastname: Ishiyama
authors.forename: I
authors.initials: I
authors.lastname: Imai
authors.forename: E
authors.initials: E
authors.lastname: Fukuma
authors.forename: N
authors.initials: N
authors.lastname: Miyajima
authors.forename: N
authors.initials: N
authors.lastname: Kano
authors.forename: T
authors.initials: T
authors.lastname: Yamakawa
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: J
authors.initials: J
authors.lastname: Kera
authors.forename: S
authors.initials: S
authors.lastname: Takeuchi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004755:Enterobacteriaceae; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000737:chemistry / Q000627:therapeutic use*; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000737:chemistry / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D008970:Molecular Weight; D013274:Stomach Neoplasms / Q000473:pathology*
chemical_list: D007155:Immunologic Factors; D008070:Lipopolysaccharides; D015251:Epirubicin; D016685:Mitomycin; D005472:Fluorouracil